The standard of care and the facts are simple. Men who have aggressive prostate cancer and elect to have radiation therapy will benefit from six months of concurrent hormone therapy (ADT). However, based on recent findings by D’Amico etal, there seems to be a segment of men who will not benefit, but will have inferior [...]
The Prostate Cancer Patient Action Leadership Council will meet in late October to plan advocacy events and activities for 2016. You are invited to join. Please sign up at: http://malecare.org/about/survivor-family-friends-advisory-board/
Xgeva, also known as denosumab, is an injectable medication (injected once a month subcutaneously under the skin in the doctor’s office) that is used to prevent bone fractures and spinal cord compression caused by bone metastases in breast and prostate cancer survivors. Solid tumors in the bone, which is a common site for individuals with [...]
FROM this blog on September 9, 2015 ) According to Michael Jan, MD, and his collaborators at the Karolinska Institute in Stockholm, Sweden those of us who are experiencing high levels of stress need to be cautious. Their findings boil down to the fact that our stress could allow our prostate cancer to kill us. [...]
In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]